Biotech of the Week: Covagen, binding proteins to antibodies for Immunotherapy

22/04/2016 - 2 minutes

We say our goodbyes to Belgium this week and head one more time to Switzerland. In Zürich, where you can find almost any kind of cheese, delicious chocolate and a beautiful view of the Swiss Alps near the city lake, is also where Covagen, our Biotech of the Week is located.

covagen_biotech_switzerland_fynomabs

City: Zürich (Switzerland)

Founded: 2007

Employees: 23 (as of 11/2015)

Market cap: €98.5M (on 13/04/2016)

CEO: Julian Bertschinger

Julian_Bertschinger_cilag_covagen_biotech

Mission: Founded by Julian Bertschinger and Dragan Grabulovski in 2007 , Covagen is a spin-off company of ETH Zurich which was later acquired in 2014 by Cilag (an affiliate of the Janssen / J & J).

By binding proteins to antibodies, Covagen develops therapeutic models to treatment inflammatory diseases and cancer. These antibodies are generated from research and development of their patented Fynomers (small binding proteins derived from the human Fyn SH3 domain),

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!